More research is required in order to determinate the exact tumor risk associated with MEN4 and to develop a screening protocol, though finding a CDKN1B pathogenic mutation should lead to periodical clinical, biochemical, and radiological screening similar to MEN1 patients until new recommendations arise [63]. This evidence concerns the gene MEN1 and neoplasm.